About this episode
Dr. Jonathan Keats discusses the COMPASS study and advancements in multiple myeloma treatment.
March is Multiple Myeloma Awareness Month. In this episode, we speak with TGen Associate Professor Jonathan Keats, Ph.D. Dr. Keats’ revisits the COMPASS study from the Multiple Myeloma Research Foundationm a 12-year research project that examined the different forms of this blood cancer and revealed why some patients respond well to treatment while others face more aggressive disease. His work on the project led to the development of two advanced tests that can deliver results in days instead of weeks, helping doctors choose the most effective treatment for each patient. These tests can also show when some patient may no longer need therapy, sparing many people from years of difficult and costly treatments. Listen as Dr. Keats shares why he believes the future is becoming much brighter for patients with multiple myeloma and other forms of cancer.
People in this episode
Guest: Dr Jonathan Keats
Topics covered
- Multiple Myeloma
- COMPASS study
- cancer treatment
- blood cancer
Keywords
- TGen
- research
- advanced tests
- treatment selection
Mentioned in this episode
Products: advanced tests
More episodes of TGen Talks
- Episode 90: Study Links Obesity and Cancer · March 26, 2026 · 20 min
- Episdoe 88: Closing in on One Million · December 1, 2025 · 22 min
- Episode 87: From Deadly to Detectable? · October 30, 2025 · 20 min
- Liquid Biopsy TGT September · September 30, 2025 · 26 min
- Episode 85: Runway for Research · August 26, 2025 · 12 min
- Episode 84 Precision Medicine · July 29, 2025 · 26 min
Explore listener stats, chart rankings, contacts and more on the TGen Talks podcast page.